LAS VEGAS, NEVADA -- (MARKET WIRE) -- May 16, 2007 -- Metabolic Research, Inc. (OTCBB: MTBR) announced today that it has acquired the principal assets relating to metabolically engineered drug development, formulas, prototypes, packaging design and marketing rights from Partners in Science Holdings, Inc. The acquisition was completed through an “all stock” transaction utilizing restricted common shares of the Company.
Included in the purchase are 15 product formulations, branding for four trademarks/trade names, six provisional patent applications, two technologies ready for patent filing, three contract executives, and one marketing contract, all of which should enable the Company to enter the market during the current quarter.
“This transaction should accelerate Metabolic Research’s path to profitability. We are a fully reporting OTC company with a complete line of dynamic state-of-the-art products tailored to a dramatically growing demand for natural, bio-identical, pharmaceutical grade products. We have no debt, a positive balance sheet, and funds committed to take us into profitability. This acquisition should prove to be the catalyst we need to quickly move from the R&D phase into one where we realize increasing revenues and profits, thus building long-term equity for our shareholders,” says Dr. David Summers, D.Sc., Ph.D., Chief Executive Officer of Metabolic Research, Inc.
Metabolic Research plans to utilize this technology to further its research and development of a new form of natural anti-inflammatory and analgesic products, both pharmaceuticals and nutraceuticals, for the treatment of arthritis and other inflammatory diseases.
About Metabolic Research, Inc.
Metabolic Research, Inc. intends to develop a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat inflammatory diseases. Metabolic Research’s proprietary process is based on “growing” drugs by using natural metabolic processes of plants or fungus rather than chemical synthesis used by traditional pharmaceutical companies. For more information, please visit the company’s website at: www.metabolicresearchinc.com.
This press release may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The Company’s actual results could differ materially from those anticipated in the forward-looking statements. The Company refers you to the cautionary statements and risk factors set forth in the documents it files with the Securities and Exchange Commission. Neither the Company or Phoenix IR Associates is under any obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts: Phoenix IR Associates Tony Drake 1-866-824-6931 Email: phoenix-ir@earthlink.net
SOURCE: Metabolic Research, Inc.
